サボリチニブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
説明
Savolitinib selectively inhibits the MET receptor, blocking the PI3K/AKT/MAPK-signaling
pathway as well as downregulating MYC.
使用
Savolitinib is a potent and highly selective c-Met inhibitor. Savoltinib demonstrated anti-tumor efficacy in a panel of cMet-dysregulated gastric cancer PDX models. Savolitinib also demonstrated good antitmuor activities.
臨床応用
It is currently being evaluated
in phase I clinical trials in combination with EGFR TKIs in NSCLC patients.
サボリチニブ 上流と下流の製品情報
原材料
準備製品